首页> 外文期刊>中国神经再生研究(英文版) >No synergism between bis(propyl)-cognitin and rasagiline on protecting dopaminergic neurons in Parkinson’s disease mice
【24h】

No synergism between bis(propyl)-cognitin and rasagiline on protecting dopaminergic neurons in Parkinson’s disease mice

机译:双(丙基)-认知素和雷沙吉兰在保护帕金森病小鼠中的多巴胺能神经元上没有协同作用

获取原文
获取原文并翻译 | 示例
       

摘要

Rasagiline, a monoamine oxidase-B inhibitor, and bis(propyl)-cognitin (B3C), a novel dimer are reported to be neuroprotective. Herein, the synergistical neuroprotection produced by rasagiline and B3C was investigated in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mice of Parkinsonism. By using neurobehavioural tests, high-performance liquid chromatography and western blot assay, we showed that B3C at 0.3 mg/kg, rasagiline at 0.02 mg/kg, as well as co-treatment with B3C and rasagiline prevented MPTP-induced behavioural abnormities, increased the concentrations of dopamine and its metabolites in the striatum, and up-regulated the expression of tyrosine hydroxylase in the substantia nigra. However, the neuroprotective effects of co-treatment were not signiifcantly improved when compared with those of B3C or rasagiline alone. Collectively, we have demonstrated that B3C at 0.3 mg/kg and rasagline at 0.02 mg/kg could not produce synergistic neuroprotective effects.
机译:据报道,Rasagiline,单胺氧化酶-B抑制剂和双(丙基) - 核苷酸(B3C),是一种新的二聚体是神经保护的。在此,在1-甲基-4-苯基-1,2,3,6-四氢吡啶(MPTP)诱导的帕金森病小鼠中研究了rasagiline和B3c产生的协同神经保护作用。通过使用NeurobeAvioural试验,高性能液相色谱和Western印迹测定,我们表明B3C为0.3mg / kg,罗萨里宁,rasagiline为0.02mg / kg,以及与B3c和rasagiline的共同治疗,预防MPTP诱导的行为异常,增加纹状体中多巴胺及其代谢产物的浓度,上调了酪氨酸羟化酶在基础上的表达。然而,与单独的B3C或Rasagiline相比,共治疗的神经保护作用并未显着改善。统称,我们已经证明,B3C为0.3mg / kg和0.02mg / kg的rasagline不能产生协同的神经保护作用。

著录项

  • 来源
    《中国神经再生研究(英文版)》 |2016年第8期|1339-1346|共8页
  • 作者单位

    Institute of New Drug Research and Guangzhou Key Laboratory of Innovative Chemical Drug Research in Cardiocerebrovascular Diseases, Jinan University College of Pharmacy, Guangzhou, Guangdong Province, China;

    Institute of New Drug Research and Guangzhou Key Laboratory of Innovative Chemical Drug Research in Cardiocerebrovascular Diseases, Jinan University College of Pharmacy, Guangzhou, Guangdong Province, China;

    Institute of New Drug Research and Guangzhou Key Laboratory of Innovative Chemical Drug Research in Cardiocerebrovascular Diseases, Jinan University College of Pharmacy, Guangzhou, Guangdong Province, China;

    School of Medicine, Ningbo University, Ningbo, Zhejiang Province, China;

    Department of Applied Biology and Chemical Technology, Institute of Modern Chinese Medicine, The Hong Kong Polytechnic University, Hung Hom, Hong Kong Special Administrative Region, China;

    Institute of New Drug Research and Guangzhou Key Laboratory of Innovative Chemical Drug Research in Cardiocerebrovascular Diseases, Jinan University College of Pharmacy, Guangzhou, Guangdong Province, China;

    State Key Laboratory of Quality Research of Chinese Medicine and Institute of Chinese Medical Sciences, University of Macau, Taipa, Macao Special Administrative Region, China;

    Department of Applied Biology and Chemical Technology, Institute of Modern Chinese Medicine, The Hong Kong Polytechnic University, Hung Hom, Hong Kong Special Administrative Region, China;

    Institute of New Drug Research and Guangzhou Key Laboratory of Innovative Chemical Drug Research in Cardiocerebrovascular Diseases, Jinan University College of Pharmacy, Guangzhou, Guangdong Province, China;

  • 收录信息 中国科学引文数据库(CSCD);中国科技论文与引文数据库(CSTPCD);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号